Molecular Docking, Synthesis and Biological Evaluation of New Benzimidazole‐Pyridine Derivatives as Potential Aromatase Inhibitor for the Treatment of Cancer

Abstract This study describes the synthesis of N 5 ‐(4‐(1 H ‐benzo[ d ]imidazol‐2‐yl)phenyl)‐N 2 ‐phenylpyridine‐2,5‐diamine derivatives from Orthophenylenediamine ( 1 ) and 4‐aminobenzoic acid ( 2 ) and all the synthesized chemical moieties screened against a panel of cancer cell lines resulted in the identification compound 6 a with good anti‐cancer potential and a GI 50 of 2.95 μ M, 3.35 μ M, 2.27 μ M, 8.46 nM and 1.56 μ M against MDAMB‐231, MCF‐7, A‐549, NCI‐H23 and A‐498 respectively. As the second greatest cause of death globally, cancer continues to pose a serious threat to public health. An essential enzyme called aromatase catalyses the last, rate‐limiting step in the production of oestrogens. As a well‐researched endocrine therapeutic strategy, aromatase inhibitors (AIs) efficiently block the production of oestrogen, which is necessary for aromatase activity.